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Background: In Chile, significant reductions in cervical cancer incidence and mortality have been observed due to
implementation of a well-organized screening program. However, it has been suggested that the inclusion of
human papillomavirus (HPV) vaccination for young adolescent women may be the best prospect to further reduce
the burden of cervical cancer. This cost-effectiveness study comparing two available HPV vaccines in Chile was
performed to support decision making on the implementation of universal HPV vaccination.
Methods: The present analysis used an existing static Markov model to assess the effect of screening and
vaccination. This analysis includes the epidemiology of low-risk HPV types allowing for the comparison between the
two vaccines (HPV-16/18 AS04-adjuvanted vaccine and the HPV-6/11/16/18 vaccine), latest cross-protection data on
HPV vaccines, treatment costs for cervical cancer, vaccine costs and 6% discounting per the health economic
guideline for Chile.
Results: Projected incremental cost-utility ratio (ICUR) and incremental cost-effectiveness ratio (ICERs) for the
HPV-16/18 AS04-adjuvanted vaccine was 116 United States (US) dollars per quality-adjusted life years (QALY) gained
or 147 US dollars per life-years (LY) saved, while the projected ICUR/ICER for the HPV-6/11/16/18 vaccine was 541
US dollars per QALY gained or 726 US dollars per LY saved. Introduction of any HPV vaccine to the present cervical
cancer prevention program of Chile is estimated to be highly cost-effective (below 1X gross domestic product
[GDP] per capita, 14278 US dollars). In Chile, the addition of HPV-16/18 AS04-adjuvanted vaccine to the existing
screening program dominated the addition of HPV-6/11/16/18 vaccine. In the probabilistic sensitivity analysis results
show that the HPV-16/18 AS04-adjuvanted vaccine is expected to be dominant and cost-saving in 69.3% and 77.6%
of the replicates respectively.
Conclusions: The findings indicate that the addition of any HPV vaccine to the current cervical screening program
of Chile will be advantageous. However, this cost-effectiveness model shows that the HPV-16/18 AS04-adjuvanted
vaccine dominated the HPV-6/11/16/18 vaccine. Beyond the context of Chile, the data from this modelling exercise
may support healthcare policy and decision-making pertaining to introduction of HPV vaccination in similar resource
settings in the region.
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Cervical cancer is the second most common cancer in
women of the Latin America and Caribbean (LAC) region
with estimated age-standardized incidence and mortality
rates of 23.5 and 10.8 per 100,000 women, respectively [1].
Organized screening programs based on cytology have
reduced the cervical cancer burden through early detection
and treatment of pre-cancerous lesions [2,3]. Very few
countries from the LAC region have shown a slight
decrease in cervical cancer disease burden following imple-
mentation of screening programmes [4,5]. This may be due
in part to difficulties in the implementation of organized
screening programs in these low-resource settings. More-
over, ensuring utilization of services provided through
these screening programs poses an additional challenge in
this region. There is great disparity in the approach
between countries to reduce the burden of cervical cancer
in the LAC region. Countries like Chile have a well-
organized screening program and therefore low cervical
cancer morbidity and mortality compared to other coun-
tries in the LAC region. Chile is one of the few countries
in this region with a functional organized screening pro-
gram [6]. A 162% increase in Papanicolaou’s (Pap) smear
testing coverage (1990–2004), and a 48.0% decrease in
cervical cancer mortality (1987–2003) were observed in
Chile after the implementation of the screening programme
[7,8]. In most of the other countries in the LAC region
where no screening programs exist, the incidence and
mortality associated with cervical cancer remain high [1].
New opportunities to tackle this high burden of cervical
cancer disease are now available. Two different vaccines
against human papillomavirus (HPV) have been widely
used, both internationally and in the LAC region [3,9]. It
is expected that these vaccines if combined with existing
screening programs could become a critical component of
cervical cancer prevention programs [9].
Cost-effectiveness analysis of new interventions, like
the introduction of HPV vaccines is a useful tool to
assist decision makers in allocating resources. Results
reported from these analyses vary widely from one
country to another due to epidemiological variation,
treatment-related costs and effectiveness of existing sec-
ondary prevention programs. The potential impact and
cost-effectiveness of introducing the bivalent HPV-16/18
AS04-adjuvanted vaccine to the cervical cancer prevention
programs of five Latin American countries was previously
evaluated [10]. That analysis has shown that the incre-
mental cost-effectiveness ratio (ICERs) was higher for
Chile where a successful screening program existed [10].
For countries like Chile it is therefore more difficult to
achieve a good and robust cost-effectiveness profile.
HPV vaccines have now been offered to Latin American
countries through the Pan American Health Organization
(PAHO) Revolving Fund at low prices per vaccine dosefollowing which some countries in the LAC region have
decided its inclusion in their national vaccination pro-
grams (Panama, Mexico, Peru and Argentina) [11]. The
present cost-effectiveness and cost-utility analysis was
performed to assess the feasibility of including a HPV
vaccination program to the current screening program
in Chile while updating the original model and input
parameters based on availability of new data [10]. This
analysis includes the latest cross-protection data for
both HPV vaccines, up to-date treatment costs for cer-
vical cancer generated by the Ministry of Health of
Chile, including specific health economic recommenda-
tions for Chile on discounting, vaccine prices per dose
for the public health sector and the epidemiology of
low-risk HPV types (HPV types that rarely cause cancer
and include HPV types such as 6 and 11) allowing for
the comparison between the two HPV vaccines as well




This analysis used a previously published lifetime Markov
cohort model with a one year cycle reproducing the
natural history of oncogenic HPV in cervical cancer, the
effect of screening and of vaccination [10,12-15] during
the lifetime of the cohort. The model was previously eval-
uated in terms of its capacity, requirements, limitations
and comparability in a study conducted by the World
Health Organization [16] and has been extended by
including infection with low-risk HPV types that might
lead to the development of a cervical intraepithelial neo-
plasia (CIN) grade 1 (CIN1) lesion and genital warts
(GW) [17]. The model structure used to analyze the cost-
effectiveness of the HPV-16/18 AS04-adjuvanted vaccine
and HPV-6/11/16/18 vaccine for Chile has been described
previously [17]. The present model considers the per-
spective of the healthcare payer thereby allowing for
the comparison of three different intervention strategies –
current screening program (reference scenario), current
screening program and vaccination with the HPV-16/18
AS04-adjuvanted vaccine; and current screening program
and vaccination with the HPV-6/11/16/18 vaccine. The
model was validated against reported cervical cancer
incidence, cervical cancer death and GW incidence.
Input parameters
Most of the input parameters used to calibrate the
model for Chile were previously described [10] and are
summarized in Table 1.
Vaccinated population and coverage
The vaccinated cohort assumed in the model included
women aged 11 years (n = 123581; population statistics,
Table 1 Input data, base case
Population data
11-years old women cohort (2012) 123,581 [18]
Screening characteristics [19]
Regular screening coverage 57.0% [20]
Interval between regular screening 3 years [10]
Irregular screening coverage 0.0%
Population without screening 43.0% [20]
Age of initiation of screening 25 years [10]
Sensitivity to detect CIN1 58.0% [10]
Sensitivity to detect CIN2 and CIN3 61.0% [10]
Estimated positive Pap smear 1.7% [10]
Treatment performance [21]
CIN1 detected by the screening
and undergoing treatmenta
40.0% [22]
Efficacy of CIN1 treatmenta 100.0% [10]
CIN1 treatment effectivenessb 40.0%
CIN2 and CIN3 detected by the
screening and undergoing treatmenta
100.0% [10]
Efficacy of CIN 2 and 3 treatmenta 90.0% [10]
CIN2 and CIN3 treatment effectivenessb 90.0%
Five-year cancer cure rate 64.0% [1]
Parameters to estimate vaccine
effectiveness
Prevalence of HPV types 16 and 18 in
cervical cancer
80.0% [23]
Prevalence of other oncogenic HPV in
cervical cancer
20.0% [23]
Prevalence of HPV types 16 and 18 in CIN23 46.5% [19]
Prevalence of other oncogenic HPV in CIN23 29.8% [19]
Prevalence of HPV types 16 and 18 in CIN1 36.5% [19]
Prevalence of other oncogenic HPV in CIN1 42.9% [19]
Prevalence of HPV types 6 and 11 in CIN1 15.8% [19]
Prevalence of HPV types 6 and 11 in GW 76.2% [24]
Vaccine efficacy to HPV types16 and 18
CC (HPV-16/18 & HPV-6/11/16/18 vaccines)
98.0%/98.0% [25-27]
Vaccine efficacy to HPV types16 and 18
CIN23 (HPV-16/18 & HPV-6/11/16/18 vaccines)
98.0%/98.0% [25-27]
Vaccine efficacy to HPV types16 and 18
CIN1 (HPV-16/18 & HPV-6/11/16/18 vaccines)
98.0%/98.0% [25-27]
Vaccine efficacy to other oncogenic HPV
CC (HPV-16/18 & HPV-6/11/16/18 vaccines)
68.4%/32.5% [28-31]
Vaccine efficacy to other oncogenic HPV
CIN23 (HPV-16/18 & HPV-6/11/16/18 vaccines)
68.4%/32.5% [28-31]
Vaccine efficacy to other oncogenic HPV CIN1
(HPV-16/18 & HPV-6/11/16/18 vaccines)
47.7%/23.4%
[28,29,32]
Vaccine efficacy to HPV types 6 and 11 for
HPV-6/11/16/18 vaccine
98.0% [33,34]
Costs [35] US dollars
Pap smear cost (including false positive tests) 26.19
Table 1 Input data, base case (Continued)
GW treatment 62.00
CIN1 treatment & follow-up cost 1,636.00
CIN2 and CIN3 treatment & follow-up cost 1,636.00
Cervical cancer treatment 13,218.00
Cost per vaccinated woman
(price parity between vaccines)c
60.00
aExpert opinion; ES; bCalculated; cPrice parity at 20 US dollars per dose
were used.
Note: CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; US:
United States.
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95.0% (complete schedule at 12 years of age); this was
based on similar assumptions made by health authorities
in Chile [35].
Epidemiological data
In the present analysis new or modified epidemiological
parameters compared with the previous Chilean adaptation
of the model are described. The proportion of CIN1 cases
under treatment were reduced to 40.0% following the new
clinical guidelines developed by the Ministry of Health,
Chile [22]. Five-year cervical cancer cure rate was updated
to 64.0%.The coverage of regular screening during 2009
and 2010 was reported to be 56.7% [20]. The age-specific
incidence of low-risk HPV was calculated from prevalence
data and progression and regression rate; the method used
is detailed in Additional file 1 [36]. The incidence of GW
was calculated based on the number of reported cases in
women by the Ministry of Health, Chile (n = 4685; 2008)
[35]. Age distribution of GW was matched to data reported
in a French study [37] since this was not available for Chile.
The transition from low risk HPV infection and GW inci-
dence was estimated from the ratio between these two
parameters by age.
Medical costs
The costs of treatment of precancerous lesions and cer-
vical cancer were obtained from data published by the
Ministry of Health, Chile (Table 1) [35]. Weighted average
between reported public and private costs was used and
the original costs in Chilean Pesos (2010) were translated
to US dollars (2010) (1 US dollar = 469.7 pesos) [38].
Country-specific costs associated with HPV infection and
screening were limited to direct medical costs as reported
by the Ministry of Health, Chile [35].
Vaccine costs
The cost of vaccination was assumed to be 20 US dollars
per dose for both vaccines. Although the cost of vaccines is
slightly lower through the PAHO Revolving Fund, this
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since an accurate estimation of the cost of vaccine admin-
istration was unavailable. The cost of administration was
assumed to be the same for the two vaccines.
Vaccine efficacy and cross-protection
In the estimation of vaccine effectiveness, HPV type-
specific vaccine efficacies and HPV type prevalence in
cervical cancer and precancerous lesions for Chile were
considered. Vaccine efficacy of 98.0% against cervical
cancer, CIN1, CIN grade 2 (CIN2) and CIN grade 3 (CIN3)
associated with HPV types 16 and 18 were assumed to
be identical for the HPV-16/18 AS04-adjuvanted vac-
cine and HPV-6/11/16/18 vaccine [25-27]. Additionally,
cross-protection data was used for both vaccines (see
Additional file 1). Although there is no study directly
comparing the cross-protection benefit associated with
the HPV-16/18 AS04-adjuvanted and HPV-6/11/16/18
vaccines, analysis of the most comparable populations
from clinical trials of both the vaccines [28-32] suggest
that cross-protective vaccine efficacy estimates against
infections and lesions associated with non-vaccine
HPV types were higher for the HPV-16/18 AS04-adjuvanted
vaccines than the HPV-6/11/16/18 vaccine. Cross-protection
levels for the HPV-16/18 AS04-adjuvanted vaccine
(PATRICIA study) and HPV-6/11/16/18 vaccine (FU-
TURE I/II studies) against the ten most frequent onco-
genic HPV types after HPV types 16 and 18 (including
HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) were
selected in order to use robust estimates [28-32]. These
specific cross protection parameters against the same ten
non-vaccine and oncogenic HPV types for both vaccines
were reported from their respective clinical trials. Cross
protection considered against cervical cancer, CIN2 and
CIN3 associated with these ten oncogenic HPV types was
68.4% (HPV-16/18 AS04-adjuvanted vaccine) [29-31] and
33.0% (HPV-6/11/16/18 vaccine) [28]. Similarly, cross
protection levels against CIN1 associated with these ten
oncogenic HPV types were 47.7% (HPV-16/18 AS04-
adjuvanted vaccine) [29,32] and 23.0% (HPV-6/11/16/18
vaccine) [29]. The efficacy of HPV-6/11/16/18 vaccine
against low-risk HPV types 6 and 11 was assumed to be
98.0% [33,34]. The prevalence of HPV types in cervical
cancer, CIN1, CIN2 and CIN3 were obtained from
different studies conducted in Chile (Table 1) [19,23].
Lifetime sustained protection against HPV types 16 and
18 was considered in the base case analysis. Based on clin-
ical trial data, efficacy against the HPV-16/18 AS04-
adjuvanted vaccine after 6.4 years and 9.4 years of follow-
up was observed [21,26]. Furthermore, modelling studies
(based on 6.4 years data) have predicted long-term
(≥20 years) persistence of HPV types 16 and 18 antibodies
for the HPV-16/18 AS04-adjuvanted vaccine [39]. There-
fore, sustained protection was assumed to remain trueover a lifetime in the base case analysis and the impact
of waning effects on cost-effectiveness results was
assessed in additional scenarios (see Additional file 1).
As compliance to the recommended vaccine schedule is
often not optimal in adolescents, studies conducted in
adolescent girls have shown that a two dose schedule of
HPV-16/18 AS04-adjuvanted vaccine administered in ado-
lescents aged 9–14 years was non-inferior to a three dose
schedule administered to subjects aged 15–25 years up to
24 months post-vaccination [40]. Efficacy estimates of the
HPV-16/18 AS04-adjuvanted vaccine by dose in a non-
randomized analysis suggested that a two dose schedule of
the vaccine may be as protective as a three dose regimen
against persistent infection with HPV types 16 and 18 in
women [41]. Therefore, a potential two dose schedule for
the HPV-16/18 AS04-adjuvanted vaccine was considered as
an additional scenario of interest, based on the latest
publications of Kreimer et al. [41] and Romanovski et al.
[40]. For the two dose HPV vaccination schedule, vaccine
efficacies against the different HPV types were assumed to
be similar to the three dose schedule.
Base case analyses
The present study assessed the incremental difference in
health outcomes, total costs and ICER (cost per quality-
adjusted life years [QALY] gained) between scenarios.
Future costs and health outcomes were discounted at an
annual rate of 6.0% based on the recommendations of
the Planning Ministry of Chile [42] and used by the
Ministry of Health, Chile [22]. The effects of discount
rate on the outcomes in the different scenarios were
assessed. The discounted ICER (discounted cost per
QALY gained) estimated for each vaccination scenario
was compared to the cost-effectiveness threshold defined
by the World Health Organization [43]. Data on gross
domestic product (GDP) per capita for Chile (14278 US
dollars per capita for 2011) was obtained from the
International Monetary Fund [44].
Deterministic scenario analyses
In addition to the base case scenarios for both vaccines,
deterministic scenario analyses were conducted by varying
key input parameters of interest:
a. Prevalence of HPV types in cervical cancer cases
used for base case analysis was obtained from a
recent study [23] which reported high prevalence of
HPV types 16 and 18 (80.0% assumed for base case
scenario). As this value is slightly higher than
usually reported prevalence of 70.0% for HPV types
16 and 18 [45], additional scenarios for both the
vaccines assuming prevalence of 70.0% for HPV
types 16 and 18 and for the other oncogenic HPV
types as 30.0% were tested.
Gomez et al. BMC Public Health 2014, 14:1222 Page 5 of 13
http://www.biomedcentral.com/1471-2458/14/1222b. Discount rate of 6.0% was used in base case; however,
a discount rate of 3.0% was also tested in-line with
international guidelines.
c. Introduction of the HPV-16/18 AS04-adjuvanted
vaccine to the screening program of Chile at an
increased screening interval as a control was
considered of interest for Chile. Therefore, the
frequency of screening used in the base case was
modified from every three years to five years in the
vaccination scenario.
d. Introduction of the HPV-16/18 AS04-adjuvanted
vaccine without cross-protection, or with a
cross-protective vaccine efficacy of 45.7% (i.e.
lower limit of the 95% CI of cross protection
against cervical cancer [68.4%; 95% CI: 45.7 − 82.4])
due to the other oncogenic HPV types [30,31])
was evaluated.
e. Reduced vaccine prices (both vaccines) according to
the PAHO 2012 Revolving Fund (13.48 US dollars
per dose for the HPV-16/18 AS04-adjuvanted
vaccine and 14.25 US dollars per dose for the
HPV-6/11/16/18 vaccine) were considered.
f. The effects of waning of vaccine efficacy against
different HPV types used in the base case analysis
were assessed in different scenarios. Waning of
vaccine efficacy against HPV-18 and the other ten
oncogenic HPV types (overall ~30.0% of cervical
cancer cases) was assumed to begin 20 years after
vaccination and after five years of a linear decrease
in vaccine efficacy this value was assumed to be
negligible. This scenario of waning vaccine efficacy
was evaluated for vaccination with and without a
booster vaccine dose 21 years after the first dose
(33 years of age) administered to 95% of the cohort
and assumed to result in lifetime protection [46].
Although duration of vaccine efficacy was demon-
strated for 9.4 years (Naud et al. 2014) [21] and
neutralizing antibody levels are projected to last
more than 20 years (Naud et al. 2014 [21], David
MP et al. 2009 [39]) waning scenarios against HPV
18 and cross protected HPV types were analyzed
based on the results of the quadrivalent vaccine on
HPV 18 (Einstein MH, et al. 2011 [47] and Olsson
SE, et al. 2007 [48]) (see Additional file 1 for
details). Recent studies have shown an overall vaccine
efficacy of 93.2% (95% CI 78.9 − 98.7%) for the
HPV-16/18 AS04-adjuvanted vaccine against CIN3+
(grade 3 or worse) cases, irrespective of HPV type in
the lesion [49]. Therefore, we have also estimated the
number of cervical cancer cases and deaths averted
considering a vaccine efficacy of 93.2% reported for the
HPV-16/18 AS04-adjuvanted vaccine against CIN3+ in
an additional scenario, to show the maximum potential
impact of this vaccine.g. A vaccination program based on a two dose
schedule was analyzed for the HPV-16/18 AS04-
adjuvanted vaccine [41,42]. The two-dose schedule
for the HPV-16/18 AS04-adjuvanted vaccine investi-
gated in the present analysis assumed no difference
in vaccine efficacy compared to the three-dose
schedule. For this scenario, waning of vaccine
efficacy was also considered for some HPV types
(excluding HPV type 16 as explained earlier), or for
all oncogenic HPV types, with or without a booster
dose after 21 years of first dose (33 years of age).
Probabilistic sensitivity analyses
To test the robustness of model input data and base case
assumptions a probabilistic sensitivity analysis (PSA) was
performed to quantify the effect of uncertainty sur-
rounding the model input parameters and assumptions
on the final ICER estimates. In total, 10000 replicates
were generated from the assigned distribution to pro-
duce a distribution of the model’s results. The replicates
were plotted on the cost-effectiveness plane. The pro-
portion of replicates in each quadrant of the plane was
counted and reported as percentage. The PSA was per-
formed by comparing either the HPV-16/18 AS04-
adjuvanted vaccine or the HPV-6/11/16/18 vaccine to
screening alone or by comparing the HPV-16/18 AS04-
adjuvanted vaccine to the HPV-6/11/16/18 vaccine,
under different scenarios. The PSA was performed




The model was validated by comparing modelled out-
comes with published epidemiological parameters for
Chile which were obtained from the latest local epi-
demiological data [10,35,36]. Details on model calibra-
tion are shown in Table 2 (see Additional file 1 for
details) and are aligned with our previous estimates for
Chile [10].
The most significant health and economic outcomes
for the base case analysis are shown in Table 3. The
HPV-6/11/16/18 vaccine is projected to provide greater
benefits in the number of GW and CIN1 cases averted
whereas the HPV-16/18 AS04-adjuvanted vaccine is pro-
jected to provide greater benefits in the numbers of
CIN2 and CIN3, cervical cancer cases and deaths
averted. It is estimated that the HPV-6/11/16/18 vaccine
is projected to avert 3368 (70.0%) cases of GW and 3522
cases of CIN1 (56.4%). The HPV-16/18 AS04-adjuvanted
vaccine is projected to avert 1063 (60.6%) CIN2 and
CIN3 cases, 1172 (85.5%) cervical cancer cases and 618
(85.6%) deaths due to cervical cancer, respectively;
whereas the HPV-6/11/16/18 vaccine is projected to avert







9.7% 9.1% (15–69 years) [10,36]
Prevalence of low risk HPV
infections
3.1% 3.7% (15–69 years) [36]
Incident cases of genital
warts
4813 4685 [35]
Incident cases of cervical
cancer
1370 1331 [35]




Note: HPV: human papillomavirus.
Table 3 Outcomes for screening, screening + vaccination








Incident cases of genital
warts
4813 4813 (100%) 1445 (30.0%)
Incident cases of CIN1 6249 3100
(49.6%)
2727 (43.6%)
Incident cases of CIN23 1754 691 (39.4% ) 881 (50.2% )
Incident cases of cervical
cancer
1370 198 (14.5%) 300 (21.9 %)
Incident cases of cervical
cancer deaths
722 104 (14.4%) 158 (21.9 %)
LY 8725602 8738561 8737415



















Genital warts 396244 396334
(100.0%)
118954 (30.0%)




Vaccination costsd 7044117 7044117




aPercentage of no vaccination scenario; bScreening alone scenario; cScreening
plus vaccination scenarios; dAll costs are presented in 2010 United
States dollars.
Note: CIN: cervical intraepithelial neoplasia; LY: life years; QALY: quality-adjusted
life years.
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cancer cases and 564 (78.1%) deaths due to cervical cancer,
respectively. These differences are projected to result in a
gain of 12959/14973 life-years (LYs)/QALYs and 11813/
13770 LYs/QALYs for the HPV-16/18 AS04-adjuvanted
vaccine and HPV-6/11/16/18 vaccine, respectively.
The economic analysis projects that the introduction
of any HPV vaccine in Chile would be expected to cost
7.0 million US dollars per year (Table 3). However, the
HPV-16/18 AS04-adjuvanted vaccine is estimated to be
attributed with an additional total treatment and man-
agement cost-savings of 3.6 million US dollars in com-
parison to the HPV-6/11/16/18 vaccine (at price parity
per dose) resulting from the additional reduction in the
number of cervical cancer treatments required with the
HPV-16/18 AS04-adjuvanted vaccine compared with the
HPV-6/11/16/18 vaccine. The projected ICUR and ICER
for the HPV-6/11/16/18 vaccine compared with the ref-
erence (no vaccination) scenario was 541 US dollars per
QALY gained or 726 US dollars per LY saved, respect-
ively, while the projected ICUR and ICER for the HPV-
16/18 AS04-adjuvanted vaccine was 116 US dollars per
QALY gained or 147 US dollars per LY saved, respect-
ively (Table 4). Although the ICUR and ICER estimates
from the deterministic analysis show that the HPV-6/11/
16/18 vaccine is dominated by the HPV-16/18 AS04-
adjuvanted vaccine the introduction of either of the HPV
vaccines would be a highly cost-effective strategy in Chile
(below the 1X GDP per capita for the cost-effectiveness
threshold was 14278 US dollars). This analysis shows that
the addition of HPV-16/18 AS04-adjuvanted vaccine to
the current screening program of Chile dominates the
HPV-6/11/16/18 vaccine as it is projected to provide 29
additional QALY gains or 60 additional LYs saved at a re-
duced cost (the HPV-16/18 AS04-adjuvanted vaccine cost
344286 discounted US dollars less than the HPV-6/11/16/
18 vaccine) per year. It is also projected that both vaccines
would reach a similar ICER compared with screening
(around 110 US dollars per QALY gained) if the vaccine
price per dose for the HPV-6/11/16/18 vaccine is reduced
by 1 US dollar (19 US dollars per dose). The HPV-16/18
AS04-adjuvanted vaccine would then appear even more
attractive if only the vaccine effects over cervical cancer
(no GW considered) or the PAHO Revolving Fund vac-
cine prices per dose are considered (PAHO prices are
lower for the HPV-16/18 AS04-adjuvanted vaccine).
Probabilistic sensitivity analyses
The PSA on the ICER of the HPV-16/18 AS04-
adjuvanted vaccine (Figure 1A) and HPV-6/11/16/18
vaccine (Figure 1B) versus no vaccination (screening
alone) in the base case scenario confirms that both
vaccines are highly cost-effective (99.0% of the simula-
tions) and even cost-saving (in 51.4% of the simulations
Table 4 Cost-utility and cost-effectiveness analysis (discounted data)
a. Cost-utility
Totala





QALYs Costs QALYs Costs QALYs Costs
Current screening
practice
2126963 14272773 – – – – –
HPV-6/11/16/18 vaccine
+ current screening
2127782 14715753 819 442981 Dominated 819 442981 541
HPV-16/18 + current
screening
2127811 14371468 29 −344286 116 848 98695 116
b. Cost-effectiveness
Totala





LYS Costs LYS Costs QALYs Costs
Current screening
practice
2127239 14272773 – – – – –
HPV-6/11/16/18 vaccine
+ current screening
2127849 14715753 610 442981 Dominated 610 442981 726
HPV-16/18 + current
screening
2127909 14371468 60 - 344286 147 670 98695 147
aStrategies are listed in order of increasing health gains (QALYs). bICUR & ICER calculations for both vaccines are obtained by comparing to previous alternative
and to the reference (no vaccination) scenario. Costs and health outcomes were discounted at an annual rate of 6.0% based on the recommendations of the
Planning Ministry of Chile [42].
Note: HPV: human papillomavirus; ICUR: incremental cost-utility ratio; ICER: incremental cost-effectiveness ratio; LYS: Life-years saved; QALY: quality-adjusted
life years.
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the HPV-6/11/16/18 vaccine). Figure 1C shows that the
HPV-16/18 AS04-adjuvanted vaccine have a 69.3% chance
to dominate the HPV-6/11/16/18 vaccine although the
HPV-16/18 AS04-adjuvanted vaccine has a 8.2% chance
to result in less QALY gains with less overall costs than
the HPV-6/11/16/18 vaccine and the HPV-6/11/16/18
vaccine has a 17.5% chance to dominate the HPV-16/18
AS04-adjuvanted vaccine. These results are very sensitive
to the discount rate. The probability for the HPV-16/18
AS04-adjuvanted vaccine to dominate the HPV-6/11/16/
18 vaccine is of 93.0% (undiscounted) and 87.0% with a
3.0% discount rate.
Deterministic scenario analyses
Table 5 shows the results (cervical cancer cases and
deaths, QALYs gained, incremental costs and ICURs) for
the different scenarios of interest for both vaccines when
compared to screening alone. Considering a lower pre-
valence of HPV types 16 and 18 (70.0% in cervical can-
cer cases), the results on cases, deaths, and QALYs
gained, incremental costs and ICUR present minimal
variation. When a 3.0% discount rate was considered,
ICUR was significantly lower than base case and vaccin-
ation was projected to be cost-saving. When vaccine
introduction was combined with an increase in screen-
ing frequency (every five years), a minor reduction in
cases and deaths averted was observed with a significantreduction on the incremental costs and the ICUR result-
ing also in a cost-saving scenario. In contrast, if no
cross-protection was included in the analysis for the
bivalent vaccine, impact on cervical cancer cases, deaths
and QALYs gained was reduced by 17.0% and the incre-
mental costs and ICUR increased significantly (2305 US
dollars per QALY gained); however, vaccination is still
highly cost-effective. A cross protection vaccine efficacy
of 45.7% against cervical cancer resulted in a 6.0%
decrease in the vaccine impact on cervical cancer cases,
deaths and QALYs gained and the ICUR increased to
589 US dollars per QALY gained. When the PAHO 2012
Revolving Fund vaccine prices were considered both
vaccines were projected to be cost-saving but the HPV-
16/18 AS04-adjuvanted vaccine saved an additional
615484 US dollars. The scenario without considering
efficacy to HPV types 6 and 11 for the HPV-6/11/16/18
vaccine showed a slight decrease in QALYs gained but a
significant increase in the incremental costs and ICER
(still highly cost-effective). Waning of vaccine efficacy
starting 20 years after vaccination showed a small reduction
on vaccine impact (6.0–21.0% cases/deaths averted and
QALYs gained) with an increase observed in the incremen-
tal costs and improvement in the cost-effectiveness profile
(715 US dollars per QALY gained; but still highly cost-
effective). Additionally, if a booster dose is considered
21 years after the first dose, vaccine impact estimates
reached approximately the base case results and the ICER
Figure 1 Probabilistic sensitivity analysis (A) results for the HPV-16/18 vaccine vs. screening as comparator, (6% discount on costs and
health outcomes) (B) results for the HPV-6/11/16/18 vaccine vs. screening as comparator (6% discount on costs and health outcomes)
and (C) results for the HPV-16/18 vaccine vs. HPV-6/11/16/18 vaccine used as comparator (6% discount on costs and health outcomes).
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in a cost-effective scenario for HPV vaccination in Chile.
The scenario with only two doses of the HPV-16/18 AS04-
adjuvanted vaccine was cost-saving due to a significant
reduction (2.3 million US dollars) in the vaccination costs.
Waning of vaccine efficacy in the two dose scenarios,
slightly modified the ICER with a 6.0% to 18.0% reduction
in QALYs gained and cases or deaths averted (if vaccine
effectiveness to HPV 16 is not affected by waning) but a
21.0% to 66.0% reduction on QALYs gained and cases or
deaths averted if vaccine efficacy against HPV-16 is
affected. Nevertheless, the introduction of a booster dose
(third dose) at 33 years of age, allows for the recovery of
vaccine impact estimates on cases and deaths with an ICUR
still showing a cost-saving result (~ −1800 US dollars per
QALY gained).
Finally, when an overall vaccine efficacy for the
HPV-16/18 AS04-adjuvanted vaccine against CIN3+
cases (irrespective of HPV type in the lesion) of 93.2%
is considered the potential impact of the HPV-16/18
AS04-adjuvanted vaccine (Table 6) is greater than our
modelled estimates and is projected to avert additional
38 cervical cancer cases and 20 cervical cancer related-
deaths than those estimated by the model.Discussion
This study broadens the findings of a previous cost-
effective analysis of the HPV-16/18 AS04-adjuvanted
vaccine for Chile [10]. The analysis shows that the
introduction of HPV vaccination with either of the two
HPV vaccines is likely to prove highly cost-effective for
Chile at 20 US dollars per dose. Even in the worst case
scenarios analyzed (reduced prevalence of HPV types 16
and 18 in cervical cancer, no cross-protection, waning of
vaccine efficacy) both vaccines were highly cost-effective
for Chile. However, addition of the HPV-16/18 AS04-
adjuvanted vaccine dominated the addition of HPV-6/11/
16/18 vaccine (with a cost-saving of 47 million US dollars
when compared to screening alone [undiscounted]) to the
existing screening program of Chile. This is an important
finding for Chile where a well-organized and successful
cervical cancer prevention program (which guarantees the
access to diagnosis, treatment, rehabilitation, follow-up
and palliative care of cervical cancer cases) was developed
under the Explicit Health Warranties reform introduced
in 2003 [12].
In the alternative scenarios analyzed, even better health
and economic outcomes than the base case scenario are
estimated for Chile. When the discount rate was reduced
Table 5 Cost-utility analysis for base case and additional scenarios of interest






Base case HPV-16/18 1172 / 618 848 98695 116
Base case HPV-6/11/16/18 1069 / 564 819 442981 541
HPV-16/18 prevalence; 70% cervical cancer cases due HPV types 16 and 18d 1129 / 595 816 310450 381
HPV-6/11/16/18 prevalence; 70% cervical cancer cases due HPV types
16 and18d
977 / 516 751 887321 1181
HPV-16/18 with discounting 3%e 1172 / 618 3124 −10198541 dominantc
HPV-16/18 + regular screening (every 5 years interval)f 1158 / 612 833 −1970016 dominantc
HPV-16/18 with no cross-protectiong 976 / 515 703 1620610 2305
HPV-16/18 with cross-protection assumed as the lower value of 95%
CI to cervical cancer (68.4%; 95% CI: 45.7 − 82.4%) [30,31]g
1106 / 583 799 470344 589
HPV-16/18 price as in PAHO 2012 revolving fundh 1172 / 618 848 −2197687 dominantc
HPV-6/11/16/18 vaccine price as in PAHO 2012 revolving fundh 1069 / 564 819 −1582203 dominantc
HPV-6/11/16/18 vaccine with no VE to HPV types 6 and11i 1069 / 564 772 894820 1159
HPV-16/18 waning (HPV-18 & other oncogenic HPV) after 20 years of first
dose /during 5yj
955 / 487 794 568274 715
HPV-16/18 waning (HPV-18 & other oncogenic HPV) after 20 years of 1st
dose/during 5y + booster dose (21 years after first dose) j, k
1170 / 617 846 797020 942
HPV-16/18, 2 dose vaccine schedulel 1172 / 618 848 −2249344 dominantc
HPV-16/18 (2 doses) waning (HPV-18 & other oncogenic HPV) after 20 years
of 1st dose/during 5yj, l
955 / 487 794 −1779765 dominantc
HPV-16/18 (2 doses) waning (all HPV) after 20 years of first dose/during 5y j, l 501 / 212 681 −791887 dominantc
HPV-16/18 (2 doses) waning (HPV-18 & other oncogenic HPV) after 20 years
of first dose/during 5y + booster dose (21 years after first dosej, k, l
1170 / 617 846 −1551019 dominantc
HPV-16/18 (2 doses) waning (all oncogenic HPV) after 20 years of first
dose/during 5y + booster dose (21 years after first dose)j, k, l
1164 / 615 841 −1507808 dominantc
aCompared to no vaccination scenario; bAdditional costs compared to no vaccination scenario; cICUR is showing a cost-saving result; dBase Case: 80% prevalence;
eBase case: 6% discount; fBase case: Every 3 years interval; gBase case: CIN2/3 cross protection for bivalent vaccine 68.4% and quadrivalent vaccine 32.5%; hBase
case: vaccine cost per dose 20 US dollars for both vaccines –price parity-; iBase case: 98% vaccine efficacy; jBase case: Lifetime duration of vaccine efficacy; kBase
case: No booster dose; lBase case: 3 doses.
Note: HPV: human papillomavirus; ICUR: incremental cost-utility ratio; VE: vaccine efficacy; PAHO: Pan American Health Organization; QALY: quality-adjusted
life years.
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price was reduced to present 2012 PAHO Revolving Fund
vaccine prices or screening interval duration was in-
creased to every five years together with the vaccination
program, or a two-dose (versus three dose) vaccination
schedule for the HPV-16/18 AS04-adjuvanted vaccine was
evaluated, the implementation of cervical cancer vaccin-
ation with the HPV-16/18 AS04-adjuvanted vaccine was
cost-saving for Chile.
One of the many strengths of this analysis is the com-
parison of the cost-effectiveness profiles of the HPV-16/
18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vac-
cine for the prevention of cervical cancer updated with
recent estimates of clinical, economic and epidemio-
logical data for Chile. The ICURs for the HPV-16/18
AS04-adjuvanted vaccine (116 US dollars per QALY
gained) were dominant compared with the HPV-6/11/
16/18 vaccine (541 US dollars per QALY gained) in thebase case analysis. The PSA confirmed that the HPV-16/
18 AS04-adjuvanted vaccine remains dominant over the
HPV-6/11/16/18 vaccine (base case scenario) in 69.3% of
the simulations generated and this difference was
strengthened at lower discount rates (87.0% probability
at 3.0% discount as used in other developed countries).
Since we assumed similar vaccine efficacies against HPV
types 16 and 18 for both vaccines, the difference was
based mainly on its different cross-protection vaccine
efficacy profiles. In addition, greater benefits for the
HPV-16/18 AS04-adjuvanted vaccine can be realized if a
93.2% efficacy against CIN3+ (irrespective of HPV type
in the lesion) is considered [49]. Under this scenario, the
HPV-16/18 AS04-adjuvanted vaccine was estimated to
avert 38 and 20 additional cervical cancer cases and
deaths than those based on model type-specific vaccine
efficacy estimates, generating an even greater difference in
vaccine impact between both vaccines. In this scenario,
Table 6 Averted cervical cancer cases and deaths based on different estimation methods
Number of cases and deaths
in each scenario
Model estimated Calculated
(based on type-specific VE) (based on 93% VE to CIN3 + [47])
No vaccine HPV-16/18 HPV-6/11/16/18 HPV-16/18
95% Vaccine coverage
Cervical cancer cases 1370 198 300 160
(% of total cervical cancer) (100.0%) (14.4%) (21.9%) (11.7%)
Cervical cancer deaths 722 104 158 84
(% of total cervical cancer deaths) (100.0%) (14.4%) (21.9%) (11.7%)
80% Vaccine coverage
Cervical cancer cases 1370 406 489 351
(% of total cervical cancer) (100.0%) (29.6%) (35.7%) (25.6%)
Cervical cancer deaths 722 213 257 185
(% of total cervical cancer deaths) (100.0%) (29.5%) (35.6%) (25.6%)
Note: HPV: human papillomavirus; CIN3+ − cervical intraepithelial neoplasia type 3; VE: vaccine efficacy.
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88.3% of all cervical cancer cases and deaths while the
HPV-6/11/16/18 vaccine would avert 78.1% cervical can-
cer cases and deaths generating a difference of 140 and 74
cervical cancer cases and deaths prevented per vaccinated
cohort of Chilean women between the two HPV vaccines.
The findings from the present analysis are valid and
robust mainly due to the inclusion of many plausible
scenarios of interest. There is clinical evidence support-
ing that a two-dose schedule might be possible [40,41],
however further evidence on sustainability of vaccine
efficacy is necessary to prepare more robust simulations.
Such a scenario would make HPV vaccination cost-
saving in Chile while also potentially improving coverage
and hence public health benefit at the population level.
Nevertheless, waning of vaccine efficacy has the poten-
tial to significantly reduce vaccine benefits if it affects
the efficacy against HPV 16. If that is the case, we have
also investigated the effect of a booster dose (third dose).
The booster dose has the potential to recover the bene-
fits identified for the three-dose schedule maintaining
the cost-saving outcome for the overall schedule of two-
doses with a HPV vaccine booster dose.
The present study shows a much better cost effective-
ness profile for these vaccines than previously reported
[10]. This change may be attributed to a significant
reduction in the price per dose (aligned with present
values for the PAHO Revolving Fund), and recent data
showing an increase in the disease burden despite the
screening program in place for Chile estimated by
Globocan 2008 [1] compared to Globocan 2002 [50] and
the inclusion of updated cross-protection profiles based
on data from latest clinical trials [28-32]. The new data
released by Globocan 2012 for Chile (new estimates are
1441/734 cases and deaths) which although slightly
higher than those considered in the study, will improvethe cost effectiveness results for the vaccines but will
not modify the overall conclusions [51].
A potential limitation of this study is that the real-life
effectiveness of these vaccines is unknown or the evidence
on the sustainability of vaccine efficacy is limited. While
we have attempted to identify publications with the best
comparable estimates of cross-protection between vaccines,
there is no single trial that directly compares the cross pro-
tective efficacy of the HPV-16/18 AS04-adjuvanted and the
HPV-6/11/16/18 vaccines. In addition, modelling studies
based on vaccine efficacy after 6.4 years of follow-up for the
HPV-16/18 AS04-adjuvanted vaccine predicted a long-term
(≥20 years) persistence of vaccine-induced antibody levels
[39]. Although, there is no defined correlate of protection
between antibody levels and vaccine efficacy, the latest
evidence has shown sustained efficacy after 9.4 years of
follow-up [21]. Present estimates provide evidence of sus-
tainability of vaccine efficacy for decades, however, if vac-
cine efficacy wanes as assumed in the present analysis, a
booster dose would be required subsequent to completion
of the vaccination schedule. The analysis of waning vaccine
efficacy scenario with a booster dose have shown that even
in this worst case scenario, the vaccination program will be
highly cost-effective (three-dose schedule + booster dose).
Urgent actions are needed in order to reduce cervical
cancer mortality. Both interventions (vaccination and
screening) must be considered as complementary. Our
results show that the inclusion of vaccination against
cervical cancer to the current screening program is
highly cost-effective or even cost-saving for Chile. The
model predicts a substantial impact of the vaccination
program not only against cervical cancer cases and deaths
but also on pre-cancerous lesions and its associated
resource use (diagnostic tests and treatment). However,
controversy still exists regarding the best combination of
prevention (primary and secondary) programs against
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recent study based on an optimization model have shown
that the best combination for Brazil in the prevention of
cervical cancer cases under budget constraints was to
combine universal HPV vaccination with an increase in
screening interval [52]. We have analyzed the scenario of
vaccine implementation (base case analysis) together with
an extension of screening interval to five years and found
no significant difference in the impact of the cervical can-
cer prevention program in the prevention of cervical can-
cer cases but these combined interventions are projected
to be cost-saving for Chile. Policy makers need to be in-
formed of the progress of scientific evidence in order to
decide the best option available for each setting [7,53].
The present study is aimed to provide additional evidence
on the implementation of HPV routine vaccination in a
Latin American country like Chile whose present secondary
prevention program has attained reasonable success in con-
trolling cervical cancer. The present Chilean scenario with
reduced potential benefits for the vaccination program
when compared to other countries in the region limits the
potential capabilities of a vaccination program to have a
good cost-effective profile. However, data from this model-
ling evaluation favor the addition of HPV vaccination to the
current cervical screening program of Chile.Conclusions
The modelling exercise conducted assessed that the
implementation of HPV vaccination together with the
current screening program of Chile would be cost-
effective. These findings may further support or guide
the introduction of HPV vaccination in other countries
of the LAC region where a higher burden of cervical
cancer exists.Additional file
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